Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 


  Polysaccharide Vaccines

Meningococcal combined polysaccharide vaccines against meningitis A and B were introduced in the 1960ís and are still in use. They are effective in certain age groups, but have a poor response in children under the age of 2 years. The reason is that the immature immune system in young children is unable to recognize the polysaccharides from the coating of the bacteria as immunogenic, which is necessary in order to induce antibodies. However, the combined vaccines offer midterm protection for children and adolescents following localized outbreaks and for travelers to areas with a prevalence of serotype A.

Thus, the challenge was to develop a vaccine that can overcome the poor immunogenicity of polysaccharide vaccines. Bacteria cells have a polysaccharide capsule (an outer sugar coating protecting them from being destroyed by cells of the immune system), which was conjugated (linked) with a carrier protein (e.g. tetanus toxoid) that induces a T cell-dependent antibody response even in infants. The result is early protection of the child and long-term immunological memory (response of T cells). (9,11,14,15,16,18,23)


 » Printversion

 
 
  » find


 

Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,